Evidence map›Paper›PMID 40949101›Full record

ReviewiScience2025

Evolving tumor microenvironment: Driving cancer initiation and progression in cardiovascular diseases.

Hongyuan Cheng, Xiangjun Li, Yihan Zhong, Xiaoyan Yu, Guihua Zhou, Yinggang Zou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongyuan ChengThe Second Hospital of Jilin University, Jilin University, Changchun, China.
Xiangjun LiSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Yihan ZhongHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Xiaoyan YuSchool of Pharmaceutical Sciences, Jilin University, Changchun, China.
Guihua ZhouHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Yinggang ZouThe Second Hospital of Jilin University, Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasing aging population worldwide, the incidence rates of cardiovascular disease (CVD) and cancer have significantly risen, and there is a dynamic and complicated relationship between CVD and cancer. Epidemiological data have clearly indicated that CVD can significantly increase the incidence and mortality of cancer. In this review, we outline the common risk factors for CVD and cancer, and from the perspective of "reverse cardio-oncology," we focus on the potential mechanisms by which CVD promotes cancer development by remodeling the tumor microenvironment. We present new insights and perspectives on future research directions for the field of reverse cardio-oncology, with the ultimate goal of facilitating the development of therapeutic agents that will tailor individual treatment according to the patient's profile when multiple conditions exist.

Indexed as

Cardiovascular medicineMicroenvironmentOncology

Identifiers

PMID40949101
PMCPMC12424249

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.